mCRPC in focus
Transcript: Immune checkpoint blockade
Dr Silke Gillessen
Interview recorded September 2024. All transcripts are created from interview footage and directly reflect the content of the interview at the time. The content is that of the speaker and is not adjusted by Medthority.
So in the moment, I think immune checkpoint inhibitors in unselected patients have really not shown any benefits in patients with mCRPC. We have seen a lot of studies, and in unselected patients it doesn't work. I think I would say it like that. We had really enough studies to show that. But of course, there is this population with MSI high, and, again, we saw that again also at ESMO, just using a combination therapy. But I think the point is that patients with MSI high tumours, they can really profit from this treatment. For the moment, it's not approved in Europe in this indication, it is approved in like kind of tumour agnostic in the United States.
So for the moment, I think it's a good option for these patients. It's not something that works in all patients, but it works in quite a big percentage of patients and gives you another mechanism of action, again. But these are about 4% of the patients with mCRPC. So it's not something that you see very frequently.
Updates in your area
of interest
of interest
Articles your peers
are looking at
are looking at
Bookmarks
saved
saved
Days to your
next event
next event
Developed by EPG Health. This content has been developed independently of the sponsor, Pfizer, which has had no editorial input into the content. EPG Health received funding from the sponsor to help provide healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content. This content is intended for healthcare professionals only.